Partnerships | Anima Biotech

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

AbbVie (NYSE: ABBV), and Anima Biotech (Anima), announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology targets. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

Under the terms of the agreement, Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration.

Anima Biotech announces strategic collaboration with Takeda to discover and develop mRNA translation modulators for Neurological diseases

Anima Biotech announced an agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop mRNA translation modulators for Neurological diseases. Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize. The preclinical research collaboration will initially include Anima’s early Huntington’s Disease program against the HTT target, selectively inhibiting the mutated protein with small molecules and two additional targets named by Takeda, related to neurological diseases. Takeda will pay Anima up to approximately $120 million in upfront and preclinical research milestone payments and up to $1.1 billion in clinical and commercial milestones, assuming success of the three programs. Anima is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Takeda has a time limited option to expand the collaboration with up to three additional targets subject to additional payments to Anima of up to $1.2 billion and tiered royalties, assuming success of these programs.

Download press release

Milestone

Anima Biotech achieves first milestone in Takeda collaboration

The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.
Milestone

Anima Biotech achieves milestone in Takeda collaboration

The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.
- Download press release

Takeda coverage →

Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform. The multi-year agreement is structured as a strategic collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.

Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.